Eyepoint Pharmaceuticals Inc (EYPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) has a cash flow conversion efficiency ratio of -0.297x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.35 Million) by net assets ($200.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eyepoint Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Eyepoint Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EYPT liabilities breakdown for a breakdown of total debt and financial obligations.
Eyepoint Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eyepoint Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alma Media Oyj
HE:ALMA
|
0.088x |
|
Olectra Greentech Limited
NSE:OLECTRA
|
-0.028x |
|
Jiangsu Asia Pacific Light Alloy Technology Co Ltd
SHE:002540
|
-0.018x |
|
Instalco Intressenter AB
ST:INSTAL
|
0.133x |
|
ARB Corporation Ltd
AU:ARB
|
0.087x |
|
Zhejiang Truelove Vogue Co Ltd
SHE:003041
|
0.010x |
|
Wuzhou Special Paper Group Co. Ltd.
SHG:605007
|
0.070x |
|
Arcadyan Technology Corp
TW:3596
|
0.096x |
Annual Cash Flow Conversion Efficiency for Eyepoint Pharmaceuticals Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of Eyepoint Pharmaceuticals Inc from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see EYPT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $336.50 Million | $-126.23 Million | -0.375x | -5428.07% |
| 2023-12-31 | $266.32 Million | $1.88 Million | 0.007x | +101.04% |
| 2022-12-31 | $96.37 Million | $-65.00 Million | -0.675x | -148.27% |
| 2021-12-31 | $184.38 Million | $-50.10 Million | -0.272x | +65.10% |
| 2020-12-31 | $18.54 Million | $-14.44 Million | -0.779x | +88.56% |
| 2019-12-31 | $8.33 Million | $-56.70 Million | -6.807x | -263.12% |
| 2018-12-31 | $11.69 Million | $-21.91 Million | -1.874x | -22.00% |
| 2017-12-31 | $13.34 Million | $-20.49 Million | -1.536x | -96.63% |
| 2016-12-31 | $20.88 Million | $-16.32 Million | -0.781x | -277.33% |
| 2015-12-31 | $23.37 Million | $10.30 Million | 0.441x | +161.63% |
| 2014-12-31 | $14.92 Million | $-10.67 Million | -0.715x | +37.04% |
| 2013-12-31 | $7.70 Million | $-8.74 Million | -1.136x | -72.05% |
| 2012-12-31 | $13.64 Million | $-9.00 Million | -0.660x | -679.47% |
| 2011-12-31 | $37.43 Million | $-3.17 Million | -0.085x | -128.27% |
| 2010-12-31 | $33.04 Million | $9.90 Million | 0.300x | +183.60% |
| 2009-12-31 | $23.54 Million | $-8.44 Million | -0.358x | -51.84% |
| 2008-12-31 | $21.79 Million | $-5.14 Million | -0.236x | +26.68% |
| 2007-12-31 | $65.91 Million | $-21.21 Million | -0.322x | -32.04% |
| 2006-12-31 | $66.20 Million | $-16.14 Million | -0.244x | -58.47% |
| 2005-12-31 | $60.74 Million | $-9.34 Million | -0.154x | 0.00% |
| 2004-12-31 | $60.74 Million | $-9.34 Million | -0.154x | +24.42% |
| 2003-12-31 | $26.70 Million | $-5.44 Million | -0.204x | +71.85% |
| 2002-12-31 | $4.23 Million | $-3.06 Million | -0.723x | -- |
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more